Skip to main content
. 2022 Sep 16;101(37):e30468. doi: 10.1097/MD.0000000000030468

Table 2.

Cancer risk ratio in type 2 diabetic patients with no aspirin nor dipyridamole user, dipyridamole user, and aspirin user.

No. of cases No aspirin nor dipyridamole user Dipyridamole user Aspirin user
N (%) N (%) N (%) P value
Any type of cancer 536 135 (12.0) 150 (11.2) 251 (97) .0807
All-cause mortality 496 92 (7.8) 135 (9.5) 269 (9.9) .1134
Liver 135 46 (4.0) 34 (2.4) 55 (2.0) .0024
Colon 43 10 (0.9) 13 (0.9) 20 (0.7) .8253
Lung 67 17 (1.5) 16 (1.1) 34 (1.3) .7834
Breast 35 11 (0.9) 8 (0.6) 16 (0.6) .4144
Prostate 26 6 (0.5) 7 (0.5) 13 (0.5) .9925
Rectum 36 9 (0.8) 12 (0.8) 15 (0.6) .5197
Stomach 26 8 (0.7) 7 (0.5) 11 (0.4) .5305
Bladder 18 3 (0.3) 10 (0.7) 5 (0.2) .0207
Cervix 16 3 (0.3) 4 (0.3) 9 (0.3) .9088
Kidney 24 4 (0.3) 11 (0.8) 9 (0.3) .1069
Lymphoma 7 4 (0.3) 2 (0.1) 1 (0.0) .0567
Esophagus 10 5 (0.4) 2 (0.1) 3 (0.1) .1030
Pancreas 13 4 (0.3) 2 (0.1) 7 (0.3) .5781
Bile duct 6 1 (0.1) 0 (0.0) 5 (0.2) .2316
Larynx 3 1 (0.1) 0 (0.0) 2 (0.1) .5715
Ovary 3 0 (0.0) 1 (0.1) 2 (0.1) .6518
Thyroid 7 1 (0.1) 2 (0.1) 4 (0.1) .8799
Leukemia 1 0 (0.0) 1 (0.1) 0 (0.0) .2556